Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Histotype classification of ovarian carcinoma: A comparison of approaches.

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA.

Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.

PMID:
30121132
2.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2018 Jul 27. doi: 10.1097/PGP.0000000000000538. [Epub ahead of print]

PMID:
30059451
3.

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.

Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S.

Br J Cancer. 2018 Aug;119(4):480-486. doi: 10.1038/s41416-018-0187-6. Epub 2018 Jul 27.

PMID:
30050154
4.

Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2018 Jul 3. doi: 10.1038/s41379-018-0085-8. [Epub ahead of print]

PMID:
29968850
5.

Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, Le ND, Cook LS.

Int J Gynecol Pathol. 2018 Jun 12. doi: 10.1097/PGP.0000000000000530. [Epub ahead of print]

PMID:
29901523
6.

Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss.

Niu BT, Hammond RFL, Leen SLS, Faruqi AZ, Trevisan G, Gilks CB, Singh N.

Histopathology. 2018 Oct;73(4):703-705. doi: 10.1111/his.13663. Epub 2018 Jul 12. No abstract available.

PMID:
29852531
7.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

PMID:
29754820
8.

DICER1 hot-spot mutations in ovarian gynandroblastoma.

Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F.

Histopathology. 2018 Aug;73(2):306-313. doi: 10.1111/his.13630. Epub 2018 Jun 5.

PMID:
29660837
9.

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2018 Mar 6. doi: 10.1097/PGP.0000000000000488. [Epub ahead of print]

PMID:
29517499
10.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

PMID:
29505428
11.

TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2018 Jul;31(7):1107-1115. doi: 10.1038/s41379-018-0007-9. Epub 2018 Feb 15. Erratum in: Mod Pathol. 2018 Jul 3;:.

PMID:
29449679
12.

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A.

Ann Oncol. 2018 May 1;29(5):1180-1188. doi: 10.1093/annonc/mdy058.

PMID:
29432521
13.

Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.

Nazeran T, Cheng AS, Karnezis AN, Tinker AV, Gilks CB.

Int J Gynecol Pathol. 2018 Feb 5. doi: 10.1097/PGP.0000000000000489. [Epub ahead of print]

PMID:
29406447
14.

Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material.

Parra-Herran C, Cesari M, Djordjevic B, Grondin K, Kinloch M, Köbel M, Pirzada A, Plotkin A, Gilks CB.

Int J Gynecol Pathol. 2018 Apr 19. doi: 10.1097/PGP.0000000000000481. [Epub ahead of print]

PMID:
29369922
15.

Synchronous tumours of the female reproductive tract.

Gilks CB, Kommoss F.

Pathology. 2018 Feb;50(2):214-221. doi: 10.1016/j.pathol.2017.10.007. Epub 2017 Dec 14. Review.

PMID:
29249564
16.

Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Singh N, Faruqi A, Kommoss F, McCluggage WG, Trevisan G, Senz J, Lum A, Gilks CB, Anglesio M.

Mod Pathol. 2018 Apr;31(4):652-659. doi: 10.1038/modpathol.2017.159. Epub 2017 Nov 17.

PMID:
29148539
17.

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN.

J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi: 10.1002/cjp2.82. eCollection 2017 Oct.

18.

Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention.

Kommoss F, Gilks CB.

Clin Obstet Gynecol. 2017 Dec;60(4):686-696. doi: 10.1097/GRF.0000000000000314. Review.

PMID:
28990983
19.

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.

Kumar A, Le N, Gilks CB, Santos JL, Wong F, Swenerton K, Hoskins PJ, McAlpine JN, Tinker AV.

Int J Gynecol Cancer. 2017 Nov;27(9):1819-1825. doi: 10.1097/IGC.0000000000001124.

PMID:
28930809
20.

Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage.

Singh N, Benson JL, Gan C, Anglesio M, Arora R, Faruqi AZ, Hirschowitz L, Kommoss F, Scott K, Trevisan G, Leen SLS, Wilkinson N, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2018 Jul;37(4):324-330. doi: 10.1097/PGP.0000000000000429.

PMID:
28787323
21.

Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.

Anglesio MS, O'Neill CJ, Senz J, Gilks CB, McCluggage WG.

Histopathology. 2017 Dec;71(6):1014-1017. doi: 10.1111/his.13327. Epub 2017 Sep 22. No abstract available.

PMID:
28746984
22.

Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG.

J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.

PMID:
28678427
23.

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JM, Danielsen HE, Hoang LN.

Gynecol Oncol. 2017 Sep;146(3):596-602. doi: 10.1016/j.ygyno.2017.06.020. Epub 2017 Jun 21.

PMID:
28647100
24.

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB, Singh N.

Histopathology. 2017 Nov;71(5):736-742. doi: 10.1111/his.13272. Epub 2017 Aug 7.

PMID:
28570008
25.

Cancer-Associated Mutations in Endometriosis without Cancer.

Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.

N Engl J Med. 2017 May 11;376(19):1835-1848. doi: 10.1056/NEJMoa1614814.

26.

High-grade serous carcinoma of tubo-ovarian origin: recent developments.

Singh N, McCluggage WG, Gilks CB.

Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18. Review.

PMID:
28477361
27.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
28.

Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas.

Tessier-Cloutier B, Asleh-Aburaya K, Shah V, McCluggage WG, Tinker A, Gilks CB.

Histopathology. 2017 Sep;71(3):446-452. doi: 10.1111/his.13239. Epub 2017 Jun 16.

PMID:
28418164
29.

HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course.

McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, Prigge ES, Jordan S, Singh N, Miller DM, Gilks CB.

Int J Gynecol Pathol. 2017 Nov;36(6):507-516. doi: 10.1097/PGP.0000000000000375.

PMID:
28319571
30.

Tubal origin of ovarian high-grade serous carcinoma-time to let go of the wrong end of the stick.

Singh N, Gilks CB.

BJOG. 2017 May;124(6):879. doi: 10.1111/1471-0528.14542. Epub 2017 Mar 15. No abstract available.

31.

Ovarian carcinoma histotype in Lynch syndrome.

Gilks CB, Clarke BA, Foulkes WD.

Gynecol Oncol Rep. 2017 Mar 16;20:140-141. doi: 10.1016/j.gore.2017.03.009. eCollection 2017 May. No abstract available.

32.

Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.

McAlpine JN, Leung SCY, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN.

Histopathology. 2017 Aug;71(2):238-246. doi: 10.1111/his.13205. Epub 2017 May 23.

PMID:
28257152
33.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.

34.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):151-159. doi: 10.1097/PAI.0000000000000470.

PMID:
28187030
35.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):79-85. doi: 10.1097/PAI.0000000000000444. Review.

PMID:
28182587
36.

Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.

Köbel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, Delair D, Stewart CJR, Lee CH.

Int J Gynecol Pathol. 2017 Nov;36(6):555-561. doi: 10.1097/PGP.0000000000000369.

PMID:
28114191
37.

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Köbel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB.

Am J Surg Pathol. 2017 Feb;41(2):245-252. doi: 10.1097/PAS.0000000000000764.

PMID:
28079598
38.

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.

39.

The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century.

Singh N, Gilks CB.

Histopathology. 2017 Jan;70(1):56-69. doi: 10.1111/his.13080. Review.

PMID:
27960241
40.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.

Cheung CC, D'Arrigo C, Dietel M, Francis GD, Fulton R, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):227-230. doi: 10.1097/PAI.0000000000000469.

PMID:
27941560
41.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.

Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):4-11.

PMID:
27922482
42.

The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG.

Nat Rev Cancer. 2017 Jan;17(1):65-74. doi: 10.1038/nrc.2016.113. Epub 2016 Nov 25. Review.

PMID:
27885265
43.

FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor.

Färkkilä A, McConechy MK, Yang W, Talhouk A, Ng Y, Lum A, Morin RD, Bushell K, Riska A, McAlpine JN, Gilks CB, Unkila-Kallio L, Anttonen M, Huntsman DG.

J Mol Diagn. 2017 Jan;19(1):126-136. doi: 10.1016/j.jmoldx.2016.08.005. Epub 2016 Nov 1.

PMID:
27810330
44.

The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians.

McCluggage WG, Hirschowitz L, Gilks CB, Wilkinson N, Singh N.

Int J Gynecol Pathol. 2017 May;36(3):230-239. doi: 10.1097/PGP.0000000000000336.

PMID:
27801755
45.

Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma.

Kommoss F, Faruqi A, Gilks CB, Lamshang Leen S, Singh N, Wilkinson N, McCluggage WG.

Am J Surg Pathol. 2017 Feb;41(2):161-170. doi: 10.1097/PAS.0000000000000757.

PMID:
27776011
46.

Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva.

Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings HM.

Int J Gynecol Pathol. 2017 May;36(3):289-293. doi: 10.1097/PGP.0000000000000324.

PMID:
27662035
47.

Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.

Kommoss S, Gilks CB, du Bois A, Kommoss F.

Br J Cancer. 2016 Oct 11;115(8):993-999. doi: 10.1038/bjc.2016.273. Epub 2016 Sep 15.

48.

Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.

Ong JS, Cuellar-Partida G, Lu Y; Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Anne Doherty J, Anne Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall CK, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Chenevix-Trench G, Gharahkhani P, Neale RE, Webb PM, MacGregor S.

Int J Epidemiol. 2016 Oct;45(5):1619-1630. Epub 2016 Sep 4.

49.

Assessment of CK17 as a Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia.

Podoll MB, Singh N, Gilks CB, Moghadamfalahi M, Sanders MA.

Int J Gynecol Pathol. 2017 May;36(3):273-280. doi: 10.1097/PGP.0000000000000317.

PMID:
27513074
50.

In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.

McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, Mackenzie R, McAlpine JN, Huntsman DG, Clarke BA, Gilks CB, Lee CH.

J Pathol Clin Res. 2015 Apr 9;1(3):173-85. doi: 10.1002/cjp2.18. eCollection 2015 Jul.

Supplemental Content

Loading ...
Support Center